Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
When the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening for early detection of prostate cancer in May 2012, it caused a sea change in practice patterns among primary care physicians.
The impact of the recommendations had “a significant chilling effect,” said Sam Chang, MD, a professor of Urology at Vanderbilt University Medical Center, who moderated a panel discussion on the topic at the 2015 American Urological Association (AUA) Annual Meeting.
Obesity is more strongly associated with elevated prostate cancer (PCa) risk among African-American than non-Hispanic white men, according to a new study.
The finding is based on a prospective analysis of data from 22,673 non-Hispanic white (NHW) men and 3,398 African-American (AA) men who participated in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Study subjects had a median follow-up of 5.6 years, during which 1,723 were diagnosed with PCa.
An international team of scientists have revealed the genetic root of prostate cancers in individual men, demonstrating that tumors share common gene faults which could potentially offer new targets for treatment. Prostate cancer is the second most common cancer and second leading cause of cancer death in men.
The research, published in Nature, is part of the International Cancer Genome Consortium - a global project committed to revealing genetic changes driving prostate cancer using the most up-to-date gene-sequencing technology available.
Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer (CSI-TC) who underwent orchiectomy, according to a pair of studies published in the December and January issues of the Journal of Clinical Oncology.
“Most patients with CSI-TC are cured by orchiectomy alone,” wrote study authors led by Christian Kollmannsberger, MD, of the University of British Columbia in Vancouver. “With highly effective chemotherapy providing a safety net, ultimate cure rates approach 100% irrespective of the postorchiectomy strategy employed.” Thus, diminishing morbidities associated with treatment is a primary concern.
Among older men with high-risk prostate cancer, receiving androgen-deprivation therapy in combination with radiotherapy reduced cause-specific and all-cause mortality by as much as 50% when compared with those who received androgen-deprivation therapy alone, results from a large-scale data review showed.
In fact, men over the age of 65 with locally advanced prostate cancer risk significantly higher mortality rates if they are treated with androgen-deprivation therapy (ADT) without accompanying radiotherapy (RT), according to the authors of a study published online Jan. 5 in the Journal of Clinical Oncology.
Among men with prostate cancer, those who lead active lifestyles have better survival rates than those who don’t, a new study suggests.
There are many benefits to being physically active, but the new results suggest there are “specific effects also on the survival among prostate cancer patients,” said the study's lead author Stephanie Bonn of the Karolinska Institute in Stockholm.
Robot-assisted radical prostatectomy (RARP) confers excellent long-term control of prostate cancer (PCa), according to a study of what researchers believe is the largest series to date to look at oncologic outcomes after RARP.
For patients with bladder cancer, smoking status and primary source of information correlate with awareness of the harms of tobacco use, according to a study published in Cancer.
Clinical prognostic groupings for localised prostate cancers are imprecise, with 30—50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices in prostate cancer to improve risk stratification and complement clinical prognostic factors.
Holidays are traditionally viewed as a time to celebrate. Many people enjoy reuniting with family and friends, giving and receiving gifts, and celebrating religious traditions during this time. However, sometimes people with cancer and their loved ones feel "out of step" from the rest of the world during the holidays.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.